IMARC Group, a leading market research company, has recently releases report titled “Influenza Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global influenza diagnostics market share, report, analysis, trends, share, size, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Influenza Diagnostics Market
Influenza diagnostics refers to a variety of medical testing methods employed to confirm the presence or absence of the influenza virus in a specimen of a patient. It consists of rapid influenza diagnostic tests (RIDTs) immunoassays that can provide results spontaneously. It also conducts rapid molecular assays, which are nucleic acid amplification techniques capable of distinguishing between influenza A and B viruses. It assists in determining the type of virus, either Influenza A, B, or other, and the specific strain, which is essential for selecting the appropriate treatment. It also aids in patient management, prevents unnecessary use of antibiotics, and improves the efficiency of hospital resources.
How Big Is The Influenza Diagnostics Market?
The global influenza diagnostics market size reached US$ 893.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,461.7 Million by 2028, exhibiting a growth rate (CAGR) of 6.55% during 2023-2028.
What Are The Growth Prospects And Trends In The Influenza Diagnostics Industry?
At present, the increasing demand for influenza diagnostics as it enables prompt initiation of antiviral treatment, reducing the risk of various complications, such as pneumonia, hospitalization, and other serious issues, represents one of the crucial factors impelling the growth of the market. Besides this, the rising integration of advanced diagnostic techniques, such as molecular diagnostics and point-of-care testing (POCT), is contributing to the growth of the market. In addition, the growing awareness about the harmful impacts of the influenza virus among the masses is offering a favorable market outlook. Apart from this, the increasing occurrence of severe influenza infections in the geriatric population is supporting the growth of the market.
What Is Included In Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Product:
- Test Kit and Reagents
- Instruments
- Others
Breakup by Test Type:
- Molecular Diagnostic Tests
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Tests
- Other Molecular Tests
- Traditional Diagnostic Tests
- Rapid Influenza Diagnostic Tests
- Viral Culture Tests
- Direct Fluorescent Antibody Test
- Serological Tests
Breakup by Type of Flu:
- Type A Flu
- Type B Flu
- Type C Flu
Breakup by End User:
- Hospitals
- Diagnostic Laboratories
- Others
Diagnostic Centres Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who Are The Key Players Operating In The Industry?
The report covers the major market players including:
- Abbott Laboratories
- Becton Dickinson and Company
- Coris Bioconcept
- Danaher Corporation
- DiaSorin S.p.A.
- Hoffmann-La Roche Ltd (Roche Holding AG)
- Hologic Inc.
- Meridian Bioscience Inc.
- Qiagen N.V, Quidel Corporation
- Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
- and Siemens Healthineers AG (Siemens AG)